Newrite Medical key facts
as of Oct 2026- Developer of targeted therapeutic and diagnostic agents for nuclear medicine applications.
- Newrite Medical is valued at approximately $32.7M as of Oct 2026 (last reported valuation).
- It has raised $330.9M; the latest was Later Stage VC ($145.0M) in Apr 2026.
- Notable investors include Shenzhen Capital Group, Co-Stone Capital, Highlight Capital, Sichuan Venture Capital, Chengdu Venture Capital Group — 28 tracked in total.
- Status: Privately Held (backing).
Newrite Medical's last reported valuation, Aug 2018. Nothing priced has surfaced since.
- ·The complete investor list: 28 names
- ·Watch Newrite Medical: the Monday email on marks, rounds and moves
Newrite Medical funding rounds
No funding rounds for Newrite Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Newrite Medical
28+Membership and data by Private Market View
Newrite Medical valuation
Newrite Medical's last reported valuation was $32.7 million in Aug 2018. No priced round, secondary trade or fund mark has surfaced since.
Newrite Medical investors
28 investors are on record for Newrite Medical, including Shenzhen Capital Group, Co-Stone Capital, Highlight Capital and Sichuan Venture Capital. By type, the record holds 4 venture capital firms and 1 private equity firm.
About Newrite Medical
Developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company offers radiopharmaceutical development, isotope production, and radioligand therapy technologies, enabling healthcare providers to perform precision imaging and minimally invasive treatment of cancer and related diseases.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 90
- Website
- nrtmedtech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.